KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Change in Accured Expenses (2016 - 2025)

Jazz Pharmaceuticals has reported Change in Accured Expenses over the past 16 years, most recently at -$22.9 million for Q4 2025.

  • Quarterly results put Change in Accured Expenses at -$22.9 million for Q4 2025, up 76.06% from a year ago — trailing twelve months through Dec 2025 was $28.0 million (up 171.34% YoY), and the annual figure for FY2025 was $28.0 million, up 171.34%.
  • Change in Accured Expenses for Q4 2025 was -$22.9 million at Jazz Pharmaceuticals, down from $126.3 million in the prior quarter.
  • Over the last five years, Change in Accured Expenses for JAZZ hit a ceiling of $181.0 million in Q1 2025 and a floor of -$256.4 million in Q2 2025.
  • Median Change in Accured Expenses over the past 5 years was $24.2 million (2021), compared with a mean of $13.7 million.
  • Biggest five-year swings in Change in Accured Expenses: soared 722.22% in 2021 and later tumbled 775.85% in 2025.
  • Jazz Pharmaceuticals' Change in Accured Expenses stood at $48.8 million in 2021, then soared by 203.41% to $148.1 million in 2022, then plummeted by 64.21% to $53.0 million in 2023, then plummeted by 280.51% to -$95.7 million in 2024, then surged by 76.06% to -$22.9 million in 2025.
  • The last three reported values for Change in Accured Expenses were -$22.9 million (Q4 2025), $126.3 million (Q3 2025), and -$256.4 million (Q2 2025) per Business Quant data.